Five Potential Blockbuster Oncology Approvals To Look Out For In 2023
With help from Biomedtracker, Scrip takes a look at five drug candidates in oncology poised to win a US thumbs up next year. These novel assets, including three bispecific antibodies, could attract blockbuster figures, according to industry observers.
You may also be interested in...
Investigational products from Minoryx and a host of other companies targeting a range of diseases are now under review by the European Medicines Agency for potential EU approval.
In this week's podcast edition of Five Must-Know Things: a look ahead at potential oncology blockbuster approvals; strong data for Mirati’s KRAS contender in colorectal cancer; Keytruda’s architect reflects in its great success; Amgen’s waiting game for ChemoCentryx; and a look at dynamics in China’s sizzling immuno-oncology market.
The Paris-headquartered company has thrown in the towel on its oral SERD, leaving Roche, Eli Lilly and AstraZeneca to pursue Menarini in the field.